Navigation Links
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
Date:4/21/2008

First Patient Dosed in Phase 1 Trial of SBI-087, Trubion's Next-Generation

Candidate

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing SBI-087 and other CD20-directed products. SBI-087 for RA builds on Trubion and Wyeth's clinical experience with Trubion's lead compound, TRU-015, and is based on Trubion's Small Modular ImmunoPharmaceutical (SMIP(TM)) technology.

The Phase 1 SBI-087 dose escalation clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of SBI-087 in patients with RA. Preclinical research suggests that SBI-087, a fully humanized CD20-directed SMIP, has enhanced potency in B-cell depletion in vivo compared with Rituxan. This Phase 1 trial is designed to enroll patients who meet the criteria for RA with Functional Class I, II or III, and who have been diagnosed with RA more than six months prior to the study with onset of RA after the age of 16.

With SBI-087, Trubion's pipeline now includes two differentiated compounds under development for the treatment of autoimmune and inflammatory diseases: TRU-015 and SBI-087. Trubion and Wyeth are leveraging Trubion's
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN FRANCISCO , Aug. 31, 2015  On ... District of Oregon denied motions ... Inc. (NASDAQ: GALE ) and certain of its ... had facilitated a "pump and dump" scheme to artificially ... trading period while the stock price was inflated, sold ...
(Date:8/31/2015)... 31, 2015  Regulatory affairs professionals work at ... are often strict and legislation is ever-changing. The ... for professionals who have a deep understanding of ... product lifecycle and demonstrate its use across various ... California, Irvine Extension , in partnership with the ...
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
Breaking Medicine Technology:Galena Biopharma, Inc. Stock Alert: Schubert Firm Investigates Potential Breaches of Fiduciary Duty 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.,(Nasdaq:AVII) ... target patient enrollment and released six-month,follow-up data from ... trial, currently being held in Germany, was designed ... Resten-MP(TM), when,used in conjunction with the placement of ...
... Fail to Demonstrate Meaningful Placebo Adjusted Weight,Loss; ... July 09, 2007 /PRNewswire-FirstCall/ -- Manhattan,Pharmaceuticals, Inc. ... 2a clinical trials of oral Oleoyl-estrone (OE). ... one,in common obesity and the other in ...
Cached Medicine Technology:AVI BioPharma Partner Cook Medical Announces Completion of Patient,Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of,Cardiovascular Disease 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4
(Date:9/1/2015)... ... September 01, 2015 , ... Dr. Trace Curry successfully ... of Cincinnati. In the last month the FDA has approved two intra-gastric balloons, ... These procedures represent the first incisionless, reversible, weight loss procedures available to Americans. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... for Alfresco, a next-generation customer communications archiving solution integrated with Alfresco‘s enterprise ... from Crawford and helps organizations save millions of dollars in printing costs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and pick-up artists about their experiences of female beauty, women’s emotions, fertility, female ... penis issues, as well as their relationships with other men, documenting how the ...
(Date:9/1/2015)... York (PRWEB) , ... September 01, 2015 , ... Anthony ... of the Super Lawyers 2015 for his third consecutive year in a row. ... and accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of ... will take a look at the topic of arthritis. There are over 100 different ... explore interesting arthritis types and statistics in an effort to shed light on this ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... The Center for Aging Services Technologies (CAST) today ... in Aging Services Report" that lays out the categories ... meet the needs of aging consumers and highlights what ... This version, which can be found online at ...
... reconsider or defer purchases of imaging IT systems, ... According to Millennium Research Group,s (MRG,s) ... report, the budgetary constraints facing many health ... picture archiving and communication systems (PACS), radiology information ...
... as President and Chief Executive Officer , ... (OTC Bulletin Board: PSTX) today announced that David Bruce ... Executive Officer and will also join its Board of ... will remain involved with the company as a consultant.David ...
... weight loss surgery, the number of physicians performing these procedures has ... board-certified surgeon who is a member of the American Society of ... , ... (Vocus) January 8, 2009 -- Due to the ...
... to cellphones, especially after 9 p.m., can increase the likelihood of ... as well as those from other electrical appliances and high voltage ... the cerebrospinal fluid (CSF) and simultaneously suppress the synthesis of the ... ...
... care costs could have the unintended consequence of reducing ... two Beth Israel Deaconess Medical Center physicians suggest in ... , Citing studies in behavioral economics and psychology, Pamela ... that assigning a monetary value to every aspect of ...
Cached Medicine News:Health News:Interactive Report Maps Landscape of Technology for the Aging 2Health News:Budgetary Constraints on Health Care Facilities to Affect PACS, RIS, and CVIS Markets 2Health News:Patient Safety Technologies Announces Expansion of Senior Management Team 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 2Health News:Choosing a Highly-Trained Bariatric Surgeon Crucial as Surgical Weight Loss Procedures Rise and Less-Qualified Doctors Flood the Market 3Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 2Health News:Welsh Laboratory Discovers Natural Antidote for Sleep Disturbance Caused by Cell Phones; Don't Disturb Me! Asphalia for Natural Sleep 3Health News:Cost containment focus could have consequences for health care delivery 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: